Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.

How to buy Advaxis stock

Own Advaxis stock in just a few minutes.

Posted

Fact checked

Advaxis, Inc is a biotechnology business based in the US. Advaxis shares (ADXS) are listed on the NASDAQ and all prices are listed in US Dollars. Advaxis employs 17 staff and has a trailing 12-month revenue of around USD$253,000.

How to buy shares in Advaxis

  1. Compare share trading platforms. If you're a beginner, look for a platform with low commissions, expert ratings and investment tools to track your portfolio. Narrow down top brands with our comparison table.
  2. Open and fund your brokerage account. Complete an application with your personal and financial details, like your ID and bank information. Fund your account with a bank transfer, credit card or debit card.
  3. Search for Advaxis. Find the stock by name or ticker symbol: ADXS. Research its history to confirm it's a solid investment against your financial goals.
  4. Purchase now or later. Buy today with a market order or use a limit order to delay your purchase until Advaxis reaches your desired price. To spread out your purchase, look into dollar-cost averaging, which smooths out buying at consistent intervals and amounts.
  5. Decide on how many to buy. Weigh your budget against a diversified portfolio that can minimize risk through the market's ups and downs. You may be able to buy a fractional share of Advaxis, depending on your broker.
  6. Check in on your investment. Congratulations, you own a part of Advaxis. Optimize your portfolio by tracking how your stock — and even the business — performs with an eye on the long term. You may be eligible for dividends and shareholder voting rights on directors and management that can affect your stock.

Advaxis share price

Use our graph to track the performance of ADXS stocks over time.

Advaxis shares at a glance

Information last updated 2021-02-23.
52-week rangeUSD$0.272 - USD$1.57
50-day moving average USD$0.8214
200-day moving average USD$0.509
Wall St. target priceUSD$5
PE ratio N/A
Dividend yield N/A (0%)
Earnings per share (TTM) USD$-4.094

Buy Advaxis shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.
Name Product Stock trade fee Asset types Option trade fee Annual fee Signup bonus
Robinhood
$0
Stocks, Options, ETFs, Gold/Commodities
$0
0%
Free stock (chosen randomly with a value anywhere between $2.50 and $200)
Sign up using the "go to site" link
Make unlimited commission-free trades in stocks, funds, and options with Robinhood Financial.
Interactive Brokers
$0
Stocks, Bonds, Options
$0 + $0.65/contract, $1 minimum
0%
N/A
IBKR Lite offers $0 commissions, and IBKR Pro offers advanced tools for professional traders.
Tastyworks
$0
Stocks, Options, Cryptocurrency
Stocks & ETFs: $1/contract to open, $0 to close, $10 max/leg
Futures: $2.50/contract to open, $0 to close
0%
Get 100 shares of stock (worth $1 to $6 a share)
Open and fund a new cash or margin account with $2,000+
Trade stocks, options, ETFs and futures on mobile or desktop with this advanced platform.
Moomoo
$0 for US stocks
Stocks, Options, ETFs
$0
N/A
Trade stocks on the US, Hong Kong, Shanghai and Shenzhen markets.
TradeStation
$0
Stocks, Bonds, Options, Mutual funds, ETFs, Cryptocurrency
$0 + $0.50/contract
$50
Deposit qualifying assets of $5,000+
A platform built for all kinds of traders and all styles of trading
loading

Compare up to 4 providers

*Signup bonus information updated weekly.

The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.

Is it a good time to buy Advaxis stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Advaxis financials

Revenue TTM USD$253,000
Gross profit TTM USD$253,000
Return on assets TTM -35.31%
Return on equity TTM -75.94%
Profit margin 0%
Book value $0.387
Market capitalisation USD$98.5 million

TTM: trailing 12 months

Shorting Advaxis shares

There are currently 5.4 million Advaxis shares held short by investors – that's known as Advaxis's "short interest". This figure is 8.5% down from 5.9 million last month.

There are a few different ways that this level of interest in shorting Advaxis shares can be evaluated.

Advaxis's "short interest ratio" (SIR)

Advaxis's "short interest ratio" (SIR) is the quantity of Advaxis shares currently shorted divided by the average quantity of Advaxis shares traded daily (recently around 17.6 million). Advaxis's SIR currently stands at 0.31. In other words for every 100,000 Advaxis shares traded daily on the market, roughly 310 shares are currently held short.

However Advaxis's short interest can also be evaluated against the total number of Advaxis shares, or, against the total number of tradable Advaxis shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Advaxis's short interest could be expressed as 0.05% of the outstanding shares (for every 100,000 Advaxis shares in existence, roughly 50 shares are currently held short) or 0.0487% of the tradable shares (for every 100,000 tradable Advaxis shares, roughly 49 shares are currently held short).

Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Advaxis.

Find out more about how you can short Advaxis stock.

Advaxis share dividends

We're not expecting Advaxis to pay a dividend over the next 12 months.

Have Advaxis's shares ever split?

Advaxis's shares were split on a 1:15 basis on 29 March 2019. So if you had owned 15 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Advaxis shares – just the quantity. However, indirectly, the new 1400% higher share price could have impacted the market appetite for Advaxis shares which in turn could have impacted Advaxis's share price.

Advaxis share price volatility

Over the last 12 months, Advaxis's shares have ranged in value from as little as $0.272 up to $1.57. A popular way to gauge a stock's volatility is its "beta".

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Advaxis's is 2.8597. This would suggest that Advaxis's shares are significantly more volatile than the average for this exchange and represent a higher risk.

Advaxis overview

Advaxis, Inc., a clinical-stage biotechnology company, focuses on the discovery, development, and commercialization of proprietary Listeria monocytogenes (Lm) technology antigen delivery products in the United States. The company is developing ADXS-PSA, which is in Phase 2 clinical trials for the treatment of metastatic prostate cancer; ADXS-503 that is in Phase 1/2 clinical trials for the treatment of non-small cell lung cancer; and ADXS-504 for the treatment of prostate cancer. It is also conducting clinical studies of Lm Technology immunotherapies in the following areas of disease focused hotspot/off-the-shelf neoantigen-directed therapies; human papilloma virus-associated cancers; and prostate cancer. The company has collaborations and partnerships with Merck & Co., Inc.; OS Therapies, LLC; Aratana Therapeutics Inc.; Biocon Limited; Global BioPharma Inc.; Knight Therapeutics Inc; and others. Advaxis, Inc. was founded in 2002 and is based in Princeton, New Jersey.

Frequently asked questions

More guides on Finder

Ask an Expert

You are about to post a question on finder.com:

  • Do not enter personal information (eg. surname, phone number, bank details) as your question will be made public
  • finder.com is a financial comparison and information service, not a bank or product provider
  • We cannot provide you with personal advice or recommendations
  • Your answer might already be waiting – check previous questions below to see if yours has already been asked

Finder.com provides guides and information on a range of products and services. Because our content is not financial advice, we suggest talking with a professional before you make any decision.

By submitting your comment or question, you agree to our Privacy and Cookies Policy and finder.com Terms of Use.

Questions and responses on finder.com are not provided, paid for or otherwise endorsed by any bank or brand. These banks and brands are not responsible for ensuring that comments are answered or accurate.
Go to site